---
title: "Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278385791.md"
description: "The company announced a clinical clearance rate of 73% in the cohort receiving 200 µg at Day 57."
datetime: "2026-03-09T11:32:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278385791.md)
  - [en](https://longbridge.com/en/news/278385791.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278385791.md)
generator: "portal-rs"
---

# Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

The company announced a clinical clearance rate of 73% in the cohort receiving 200 µg at Day 57.

### Related Stocks

- [MDCX.US](https://longbridge.com/en/quote/MDCX.US.md)
- [MDCXW.US](https://longbridge.com/en/quote/MDCXW.US.md)

## Related News & Research

- [Medicus Pharma signs co-development, licensing deal with Pfizer for CD228V antibody-drug conjugate](https://longbridge.com/en/news/297910433.md)
- [Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update | MDCX Stock News](https://longbridge.com/en/news/295715209.md)
- [EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi](https://longbridge.com/en/news/294506242.md)
- [Medicus Pharma wins FDA backing for optimized Phase 2 Teverelix study in acute urinary retention](https://longbridge.com/en/news/292898007.md)
- [EXCLUSIVE: Penny Stock Medicus Pharma Findings Support Potential In Women's Health Pipeline](https://longbridge.com/en/news/282836614.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**